Ecusson de la République et du canton de Genève


Changer la couleur des liensDiminuer la taille du texteAugmenter la taille du texteImprimer la page > Why Geneva

Geneva-based OM PHARMA demonstrates strong growth in 2008

The business results of the OM PHARMA  group in 2008 have reached an all time high, with a consolidated turnover of 131.7 million CHF (unaudited results), an 18 % increase with respect to 2007. This represents worldwide sales of OM PHARMA products of 240 million CHF.
Among the record sellers, Broncho-Vaxom®, the immunostimulating bacterial extract aimed at preventing respiratory tract infections, reached 105 million CHF in local sales, a 21% increase with close to 120 million capsules being bought worldwide. The revenues of the other bacterial extract Uro-Vaxom®, prescribed for the prevention of urinary tract infections, totalled 17.3 million CHF.
About the OM PHARMA groupOM PHARMA is a Swiss-based independent biotech-pharma company founded in 1937 in Geneva, with subsidiaries in Portugal and Peru. Its global workforce totals 500 including 200 in Switzerland.The headquarters are located in Meyrin/Geneva, Switzerland, where it opened in 2005 a state of the art biotech centre for the production of its leader immunotherapeutic products, Broncho-Vaxom® and Uro-Vaxom®, recommended for the prevention of respiratory respectively urinary tract infections. Different lead products are manufactured in its other new plant in Alfragide/Lisbon, Portugal, such as the vascular medications Doxium® and Dicynone®.R&D activities are focussed on immunology, allergy and vaccines.OM PHARMA is certified ISO 9001:2000 (quality) and ISO 14001:2004 (environment).More information on
This page of content is part of the files of this website. We preserve this content to provide information on historical basis. Therefore it is not updated.